P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A by Katja Weisel, Nizar J Bahlis, Paula Rodríguez-Otero, Andrea Viqueira, Shen-Wu Wang, Sangeetha Sathiah, Douglas Robinson, Thomas O’brien, Hang Quach

Get full text

Outcome of critically ill patients receiving systemic chemotherapy on the intensive care unit by Panagiotis Karagiannis, Felix Klingler, Viktor Arelin, Winfried Alsdorf, Christina König, Kevin Roedl, Walter Fiedler, Katja Weisel, Stefan Kluge, Carsten Bokemeyer, Dominic Wichmann

Get full text

P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A by Paula Rodríguez-Otero, Hang Quach, Katja Weisel, Andrea Viqueira, Shen-Wu Wang, Phineas T. Hamilton, Tao Xie, Thomas O’brien, Nizar J Bahlis

Get full text

PB2090: SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA by Shaji Kumar, Xavier Leleu, Katja Weisel, Rakesh Popat, Samantha Craigie, Leena Patel, Abril Oliva Ramirez, Wenzhen Ge, Qiufei MA, Christian Hampp, Sundar Jagannath

Get full text

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development by Pralay Mukhopadhyay, Hesham A. Abdullah, Joanna B. Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos, Sagar Lonial

Get full text

Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-... by Katja Weisel, Meletios A. Dimopoulos, Jesús San-Miguel, Agne Paner, Monika Engelhardt, Fiona Taylor, Jennifer Lord-Bessen, Christine Yip, Mike Greenwood, Jackson Tang, Michele Cavo

Get full text

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION by Cesar Rodriguez Valdes, Katja Weisel, Rachid Baz, Akshanth Polepally, Jeremy A. Ross, Ziyi Jin, Kristin D’amico, Orlando F. Bueno, Leanne Lash Fleming, Peter Voorhees

Get full text

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells by Julia Hambach, Julia Hambach, William Fumey, William Fumey, Tobias Stähler, Anna Josephine Gebhardt, Anna Josephine Gebhardt, Gerhard Adam, Katja Weisel, Friedrich Koch-Nolte, Peter Bannas

Get full text

Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making by Sebastian Gonzalez-McQuire, Meletios-Athanassios Dimopoulos, Katja Weisel, Walter Bouwmeester, Roman Hájek, Marco Campioni, Craig Bennison, Weiwei Xu, Krystallia Pantiri, Marja Hensen, Evangelos Terpos, Stefan Knop

Get full text

P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD)... by Vania Hungria, Katja Weisel, Brooke Currie, Sue Perera, Neal Sule, Wei He, Astrid Mckeown, Sandhya Sapra, Linda Nelsen, Mary LI, Sophie Barale, Julia Boyle, Kaytlyn Mcpoyle, Meletios A. Dimopoulos

Get full text

Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display by Steffen Krohn, Ammelie Svea Boje, Carina Lynn Gehlert, Sebastian Lutz, Nikos Darzentas, Henrik Knecht, Dietrich Herrmann, Monika Brüggemann, Axel J. Scheidig, Katja Weisel, Martin Gramatzki, Matthias Peipp, Katja Klausz

Get full text

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial by Dirk Hose, Susanne Beck, Hans Salwender, Martina Emde, Uta Bertsch, Christina Kunz, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Anna Jauch, Jérôme Moreaux, Anja Seckinger

Get full text

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma by Niels Weinhold, Desiree Kirn, Anja Seckinger, Thomas Hielscher, Martin Granzow, Uta Bertsch, Gerlinde Egerer, Hans Salwender, Igor W. Blau, Katja Weisel, Jens Hillengass, Marc S. Raab, Dirk Hose, Hartmut Goldschmidt, Anna Jauch

Get full text

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study by Karthik Ramasamy, Hervé Avet-Loiseau, Cecilie Hveding Blimark, Michel Delforge, Francesca Gay, Salomon Manier, Joaquín Martinez-Lopez, Maria Victoria Mateos, Mohamad Mohty, Niels W.C.J. van de Donk, Katja Weisel

Get full text

PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULT... by Katja Weisel, Vania Hungria, Hang Quach, Sung-Soo Yoon, Paula Rodríguez-Otero, Glenn Kroog, Arijit Sinha, Anita Boyapati, Charlotte Lyon, Karen Rodriguez Lorenc, Timothy Inocencio, James Harnett, Lei Chi, Vygngley Moore, Peter Voorhees

Get full text

Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample by Abdulaziz Kamili, Paymon Ahmadi, Lisa Leypoldt, Franziska Marquard, Christoph Schaefers, Ricardo Kosch, Frederik Peters, Henrik Kusche, Tanja Zamrik, Christine Hanoun, Maximilian Seib, Evgenii Shumilov, Theo Leitner, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Susanne Ghandili

Get full text

Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based the... by Heinz Ludwig, Bela Hausmann, Martin Schreder, Wolfram Pönisch, Niklas Zojer, Stefan Knop, Eberhard Gunsilius, Alexander Egle, Andreas Petzer, Hermann Einsele, Roman Hajek, Katja Weisel, Karl Jochen Krenosz, Alois Lang, Daniel Lechner, Richard Greil, David Berry

Get full text

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy by Luca Julius Pape, Luca Julius Pape, Julia Hambach, Julia Hambach, Anna Josephine Gebhardt, Anna Josephine Gebhardt, Björn Rissiek, Tobias Stähler, Natalie Tode, Cerusch Khan, Cerusch Khan, Katja Weisel, Gerhard Adam, Friedrich Koch-Nolte, Peter Bannas

Get full text

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma by Maria Victoria Mateos, Katja Weisel, Evangelos Terpos, Sossana Delimpasi, Efstathios Kastritis, Elena Zamagni, Michel Delforge, Enrique Ocio, Eirini Katodritou, Francesca Gay, Alessandra Larocca, Xavier Leleu, Paula Rodriguez Otero, Fredik Schjesvold, Michele Cavo, Meletios A. Dimopoulos

Get full text

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma by Mohamed H. S. Awwad, Katharina Kriegsmann, Julian Plaumann, Michael Benn, Jens Hillengass, Marc S. Raab, Uta Bertsch, Markus Munder, Katja Weisel, Hans Jürgen Salwender, Mathias Hänel, Roland Fenk, Jan Dürig, Carsten Müller-Tidow, Hartmut Goldschmidt, Michael Hundemer

Get full text